{"product_id":"biomedrealty-five-forces-analysis","title":"BioMed Realty Porter's Five Forces Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Strategic Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eBioMed Realty faces nuanced competitive pressures—from tenant bargaining and specialized supplier dependencies to barriers driven by lab-capable real estate and regulatory complexity—factors that shape lease terms, capex, and growth prospects; this snapshot highlights key tensions but only scratches the surface.\u003c\/p\u003e\n\u003cp\u003eUnlock the full Porter's Five Forces Analysis to get force-by-force ratings, visuals, and actionable implications tailored to BioMed Realty for investment, strategy, or due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euppliers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScarcity of prime development land\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLand in Cambridge and South San Francisco was down to single-digit vacancy for lab-zoned parcels by Q3 2025, giving sellers leverage and pushing BioMed Realty to pay acquisition premiums often 20–35% above replacement cost to secure sites near top universities and talent pools.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized construction and laboratory fit-out contractors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialized wet-lab fit-out contractors hold high bargaining power for BioMed Realty because advanced HVAC and HEPA filtration systems plus gas handling need a small pool of experts; industry reports show lab build premiums 20–40% above standard office costs and lead times often 6–12 months, so BioMed must secure preferred-vendor agreements and allocate contingency budgets (typically 5–10% of capex) to protect timelines and regulatory compliance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCost of capital and financing providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs a REIT, BioMed Realty depends on debt and equity markets to fund capital-heavy lab and life-science developments, and by end-2025 US 10-year yields had settled near 4.2%, easing financing pressure. Large institutional lenders still set loan covenants and spreads—senior unsecured borrowing costs for comparable REITs averaged ~350 bps over swaps in 2025—so lender terms directly affect project returns. BioMed’s growth and FFO per share hinge on cost of capital: a 100 bp rise in borrowing spreads can cut project IRRs by ~1.0–1.5 percentage points. Institutional credit power therefore remains a key supplier-side constraint on margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMunicipalities and regulatory bodies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLocal governments in hubs like Boston and San Francisco supply permits and zoning; in 2024 Boston issued 18 major life‑science project approvals, showing high gatekeeper power.\u003c\/p\u003e\n\u003cp\u003eThey set limits on building heights, emissions, and community benefits; recent San Francisco rules added 15% affordable‑housing or fee equivalents, raising project costs.\u003c\/p\u003e\n\u003cp\u003eBioMed Realty must manage local politics and new sustainability mandates—LEED\/Net‑Zero targets can add 5–8% capex—affecting time to market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePermits control timelines: average 9–18 months approval\u003c\/li\u003e\n\u003cli\u003eRegulations raise capex 5–8%\u003c\/li\u003e\n\u003cli\u003eCommunity requirements can add 1–3% annual operating costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized utility and energy providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioMed Realty faces high supplier power from specialized utility and energy providers because life-science labs use 2–5x the power of offices for 24\/7 HVAC and equipment; this raises dependence where local utility competition is thin in key clusters like Boston and San Diego.\u003c\/p\u003e\n\u003cp\u003eRising U.S. commercial electricity costs up ~15% from 2020–2024 and grid decarbonization pushes capital costs onto customers, so BioMed must secure long-term contracts and on-site generation to stabilize tenant rates.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eLabs use 2–5x office power\u003c\/li\u003e\n\u003cli\u003eElectricity +15% 2020–2024 (U.S.)\u003c\/li\u003e\n\u003cli\u003eLocal monopoly utilities in major clusters\u003c\/li\u003e\n\u003cli\u003eMitigate via long-term contracts, on-site renewables\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply constraints, surging premiums \u0026amp; rising costs squeeze lab real estate returns\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSuppliers exert high power: land scarcity in Cambridge\/SF pushes acquisition premiums 20–35%; specialized lab contractors add 20–40% build premium and 6–12 month leads; lenders set spreads (~350 bps avg in 2025) that can cut IRRs 1.0–1.5 ppt per 100 bp; utilities supply constrained—labs use 2–5x office power and US commercial electricity rose ~15% 2020–2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLand premiums\u003c\/td\u003e\n\u003ctd\u003e20–35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLab build premium\u003c\/td\u003e\n\u003ctd\u003e20–40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract lead time\u003c\/td\u003e\n\u003ctd\u003e6–12 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLender spreads (2025)\u003c\/td\u003e\n\u003ctd\u003e~350 bps\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIRR sensitivity\u003c\/td\u003e\n\u003ctd\u003e-1.0–1.5 ppt \/100 bp\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eElectricity use vs office\u003c\/td\u003e\n\u003ctd\u003e2–5x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS electricity change 2020–24\u003c\/td\u003e\n\u003ctd\u003e+15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eUncovers competitive pressures, buyer and supplier influence, entry barriers, substitutes, and sector-specific disruptors—tailored to BioMed Realty’s life-science real estate position with strategic implications for pricing, occupancy, and growth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise Porter's Five Forces snapshot for BioMed Realty—quickly spot dominant pressures and prioritize strategic responses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomers Bargaining Power\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh switching costs for laboratory tenants\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe physical move of labs — shifting cryogenic freezers, biosafety cabinets, and hazardous waste systems — can cost $500k–$5M and take 3–12 months, making relocation prohibitively expensive for tenants.\u003c\/p\u003e\n\u003cp\u003eAfter building out wet labs and installing utilities, biotech and pharma tenants rarely move absent major service failure or no expansion room; BioMed Realty reported 90%+ renewal rates in key markets in 2024.\u003c\/p\u003e\n\u003cp\u003eThat high relocation friction cuts tenant bargaining power at lease renewals, letting landlords maintain rents and control lease terms unless competitive capacity appears.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCritical importance of cluster proximity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTenants in life sciences prioritize proximity to top research hubs and talent—cluster access drives collaboration and hiring; 75% of biotech firms cite location as a top lease factor per 2024 JLL life sciences report.\u003c\/p\u003e\n\u003cp\u003eBioMed Realty owns premier assets in super-clusters (Boston, San Francisco, San Diego, Research Triangle), reducing tenant alternatives and raising switching costs.\u003c\/p\u003e\n\u003cp\u003eThis geographic necessity supports pricing power: BioMed’s 2024 same-store NOI grew 6.8%, even as broader CRE rents dipped.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of large pharmaceutical anchors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA portion of BioMed Realty’s portfolio is leased to major global pharmaceutical anchors (eg, Pfizer, Roche) that control significant capital and 2024-25 R\u0026amp;D footprints, letting them push for lower rents, longer tenant improvement allowances, or early termination options; anchors accounted for an estimated 22–30% of BioMed’s stabilized NOI in 2024, boosting their bargaining leverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial health of venture-backed startups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSmaller biotech tenants rely on venture capital that tightened in 2024–2025; US VC deal value fell ~18% in 2024 to $144B and dry powder dropped to ~$185B by end-2024, so funding sensitivity raises churn risk for lab landlords.\u003c\/p\u003e\n\u003cp\u003eIf funding stalls, tenants ask for shorter leases and downsized labs, pushing demand for flexible terms; BioMed must trade higher flexibility for occupancy to avoid vacancy-driven revenue loss.\u003c\/p\u003e\n\u003cp\u003eBioMed should weigh portfolio-wide occupancy (86% Q4 2024) against higher turnover and fit-out costs when leasing to VC-backed startups.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUS VC deal value ~144B in 2024\u003c\/li\u003e\n\u003cli\u003eVC dry powder ~185B end-2024\u003c\/li\u003e\n\u003cli\u003eBioMed occupancy ~86% Q4 2024\u003c\/li\u003e\n\u003cli\u003eShorter leases raise turnover and fit-out costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemand for specialized and sustainable infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eModern life-science tenants demand high ESG (environmental, social, governance) standards and advanced tech integration; in 2024, 62% of biotech firms prioritized green-certified lab space when selecting locations.\u003c\/p\u003e\n\u003cp\u003eTenants needing specialized, high-spec environments have limited bargaining power since only a few landlords (BioMed Realty among them) deliver required technical sophistication and tenant improvements costing $300–800\/sf.\u003c\/p\u003e\n\u003cp\u003eAs more green-certified lab inventory comes online—estimated +18% national lab stock in 2024—tenant leverage will rise, letting them shop for landlords with best sustainability metrics and lower operating costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e62% of biotech firms value green-certified space (2024 survey)\u003c\/li\u003e\n\u003cli\u003eTenant improvement costs: $300–800 per square foot\u003c\/li\u003e\n\u003cli\u003eLab stock growth ~18% in 2024 increases tenant options\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Cart-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioMed: High switching costs and 90%+ renewals limit tenant leverage despite VC slowdown\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCustomers have low-to-moderate bargaining power: high relocation costs ($500k–$5M; 3–12 months), 90%+ renewals in key markets (2024), and BioMed’s presence in super-clusters raise switching costs, but anchor tenants (22–30% NOI) and VC funding declines (US VC $144B; dry powder $185B end-2024) give some leverage for concessions.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRelocation cost\u003c\/td\u003e\n\u003ctd\u003e$500k–$5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRenewal rate\u003c\/td\u003e\n\u003ctd\u003e90%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOccupancy\u003c\/td\u003e\n\u003ctd\u003e86% Q4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVC deal value\u003c\/td\u003e\n\u003ctd\u003e$144B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eBioMed Realty Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact BioMed Realty Porter's Five Forces analysis you'll receive immediately after purchase—no placeholders, no mockups, fully formatted and ready for use. The document contains the complete competitive assessment, market context, and strategic implications as presented here. Instant download follows payment, delivering the same professionally written file you see in this preview.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56747049812345,"sku":"biomedrealty-five-forces-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/biomedrealty-five-forces-analysis.png?v=1772194604","url":"https:\/\/matrixbcg.com\/products\/biomedrealty-five-forces-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}